GlassScriptPhysician profile
Jesse J Jacquez
NPI 1285644294
$2,502.90
in general payments reported to CMS, 2019-2025
14 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $540 · 2023: $657 · 2024: $716 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.31 | 2022-2025 | Jardiance |
| Abbott Laboratories | $447.35 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $386.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $374.98 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $320.30 | 2021-2025 | Mounjaro, Kisunla, Jardiance |
| Xeris Pharmaceuticals, INC. | $122.60 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $71.28 | 2021-2024 | |
| Exact Sciences Corporation | $54.30 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $46.68 | 2021-2022 | |
| Dexcom, INC. | $41.15 | 2025 | Dexcom G6 Transmitter |
| Virtus Pharmaceuticals LLC | $24.14 | 2025 | Levorphanol Tartrate |
| Astrazeneca Pharmaceuticals LP | $15.71 | 2023 | Farxiga |
| Glaxosmithkline, LLC. | $14.03 | 2025 | Shingrix |
| Medtronic, INC. | $13.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Jacquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.